Neoadjuvant Immunotherapy Expands Its Reach in Metastatic Melanoma
A number of novel immunotherapies, such as PD-1 inhibitors and targeted drug therapies with BRAF and MEK inhibitors, have become available for managing advanced melanoma.
Immune Checkpoint Inhibitors in Bladder Cancer: Refining Their Role
Emerging data demonstrate the potential of these drugs to optimize survival, preserve quality of life, and even spare patients a radical cystectomy.
New Tools Emerge to Manage Relapsed/ Refractory Multiple Myeloma
Newer approaches for patients with relapsed/refractory multiple myeloma are moving away from chemoimmunotherapy and toward drugs with novel mechanisms of action.
Garcia-Manero Calls for New Combination Approaches in MDS
An overview of the single-cell level in early stage disease and describe new molecular classifications of myelodysplastic syndrome.
2 Commerce Drive Cranbury, NJ 08512